
OR WAIT null SECS
Jay Lieberman, MD, discusses integrated dibutepinephrine sublingual film data in patients with and without allergic reaction symptoms at ACAAI 2026.
Dibutepinephrine (Anaphylm) sublingual film maintained its pharmacokinetic and pharmacodynamic profile during localized allergic reactions, according to Jay A. Lieberman, MD, professor at the University of Tennessee Health Science Center and Le Bonheur Children's Hospital, who presented an integrated analysis of the investigational epinephrine prodrug.1
Lieberman presented the late-breaking oral abstract at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting, held November 12-16, 2026, in Phoenix, Arizona. The analysis combined phase 1 data in healthy adults, compared with epinephrine autoinjectors and manual intramuscular injection, with a phase 2 study in which adults with oral allergy syndrome received the 12 mg film with and without an oral allergen challenge.1-3 In the phase 2 study, 94.4% of 36 patients had moderate or severe oral symptoms during screening challenge, and investigators concluded absorption was not diminished by oral symptoms.2
"It is hard to do these studies in true anaphylaxis, right? Put someone through anaphylaxis and then randomize them to a treatment. It is unethical in some ways, but to see data in an acute allergic reaction that's attempting to mimic anaphylaxis is very reassuring," Lieberman said.
Lieberman said epinephrine concentrations rose slightly faster and higher during the localized reaction than without symptoms, and the curves resembled those from the earlier healthy-adult studies. He noted intranasal epinephrine products were evaluated with a comparable nasal allergen challenge model.
If approved, the film would join autoinjectors and intranasal epinephrine as options, Lieberman said, adding he prescribes whichever form a patient will carry and use and the film’s small size may help with carrying. After the FDA declined to approve the film earlier this year, Lieberman said the agency’s response focused on patient experience issues.⁴
The FDA issued a complete response letter on January 30, 2026, citing deficiencies in the human factors validation study, including difficulty opening the pouch and incorrect film placement, with no manufacturing issues or questions about submitted comparability data.⁴ Aquestive modified the pouch opening, instructions for use, and labeling, and the FDA set a March 16, 2027, goal date after accepting the resubmission.⁴˒⁵ The integrated analysis has not been peer reviewed.
Lieberman’s disclosures include Aquestive Therapeutics.